GSK plc, aka GlaxoSmithKline, is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved ...

As described in Dan Pink’s book, To Sell is Human, GlaxoSmithKline (GSK), the global pharmaceutical, vaccines, and consumer health care company, has adopted a groundbreaking approach to paying its ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

In the quarter, GSK reported 5% year-over-year earnings growth at constant currency and core operating margin of 34.7%, a 1.8-percentage-point improvement over the same period last year. Management ...

GSK stock is trading higher after executive dividend reinvestment lifted ADS holdings, while fresh valuation analysis flags the shares as trading above estimated intrinsic value for US investors. GSK ...

Wide-moat GSK’s fourth-quarter earnings were in line with our expectations. The company also revised its expectation for risk-adjusted revenue in 2031 upward to GBP 40 billion, an increase of GBP 2 ...

GSK stock trades slightly lower in late August 2026 as the company secures US approval for an expanded use of HIV drug Tivicay, while investors weigh recent share moves and pipeline progress. GSK plc ...

GlaxoSmithKline ( (GB:GSK)) has shared an update. GlaxoSmithKline (GSK) has announced a transaction involving the purchase of 217,000 of its own ordinary shares, with prices ranging from 1,793.00p to ...